Abstract Details

Title Non-Interventional Study of the Switch from Oral Treatment to Rotigotine Transdermal System in Patients with Parkinson's Disease and Gastrointestinal Symptoms

Topic Movement Disorders

Presentation(s) P01 - (-)

Poster/Presentation
Number 067

Objective

Background GI symptoms are common among patients with PD, significantly affecting their quality of life. Symptoms may be related to the evident pathology of the enteric nervous system, but may also be caused by drug treatment via central effects or inhibition of intestinal motility due to D2-related stimulation of dopaminergic neurons.

Design/Methods Non-interventional, observational study conducted in a routine clinical practice setting in Germany (ClinicalTrials.gov: NCT01159691). Patients presenting with GI symptoms (eg, heartburn, bloating, nausea, vomiting, abdominal pain, diarrhea) receiving oral drug treatment were switched independently by their physician to rotigotine transdermal system. Primary efficacy outcomes included changes in GI symptoms, measured by a visual analogue scale (intensity; 0-100 mm) and the sum score of GI complaints (six items each rated 0-12 for sum score of 0-72), as well as patient satisfaction regarding GI symptoms over [sim]6 weeks after switching.

Results Of 76 enrolled patients, 58 had follow-up data available for final analysis. Intensity of GI complaints improved numerically on the visual analogue scale (47.5±24.4 mm at baseline; 19.7±23.3 mm after [sim]6 weeks) as well as the sum score of GI complaints (11.2±9.0 at baseline; 2.1±4.4 after [sim]6 weeks). Fifty of 58 patients were satisfied or very satisfied with the improvement in GI symptoms after [sim]6 weeks.

Conclusions This study suggests that a switch from oral PD medication to transdermal dopaminergic therapy (rotigotine) may improve pre-existing GI symptoms among patients with PD. Further studies are needed to confirm this finding. An ongoing double-blind trial investigating the effects of rotigotine transdermal system on GI motility will investigate this further.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Gavin Giovannoni, MD (QMUL)	Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��